Anti-IL1RL1 therapeutic antibody (Pre-made Melrilimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Melrilimab (formerly GSK 3772847) was a monoclonal antibody targeting interleukin-1 receptor-like 1 (IL1RL1 or ST2 or IL-33R), which was being developed by GlaxoSmithKline for the treatment of asthma and atopic dermatitis. Clinical development was ongoing in the US and the UK.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-340-1mg	1mg	3090
GMP-Bios-ab-340-10mg	10mg	21890
GMP-Bios-ab-340-100mg	100mg	148000
GMP-Bios-ab-340-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Anti-IL1RL1 therapeutic antibody (Pre-made Melrilimab biosimilar,Whole mAb)
INN Name	Melrilimab
Target	IL1RL1
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2020
Year Recommended	2021
Companies	GlaxoSmithKline
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Asthma;Atopic dermatitis
Development Tech	na